Biology Reference
In-Depth Information
Fig. 29.2
Fluorescence image of C2C12 myotube treated with 20 mM taurine in the Ca
2+
chelator
nifedipine treatment (
a
) and
taut
siRNA transfection (
b
) and the expression level of MCIP1 mRNA
in the myotube treated with taurine and nifedipine (
c
). (
a
,
c)
C2C12 cells were exposed to differ-
entiation medium containing 20 mM taurine with or without 10 mM nifedipine for 5 days. Myosin
heavy-chain protein in myotube was immunohistochemically stained with anti-MHC and FITC-
conjugate IgG antibodies (
c
). C2C12 cells transfected with either
control
or
taut
siRNA and GFP
vector were differentiated with 20 mM taurine (
c
). The mRNA expression level of MCIP1 was
quantified by real-time PCR and shown as the relative ratio to undifferentiated myoblast. The dif-
ferentiated myotube was detected by the transfected GFP. Data are shown as the mean ± SD and
*
P
< 0.05, †
P
< 0.001(vs. myoblast) by the unpaired Student's
t
-test and one-way AVOVA multi-
ple comparison test, respectively
treated with and without nifedipine was significantly reduced by taurine treatment
(Fig.
29.2b
). Similarly, FK-506 treatment in the C2C12 cells markedly reduced
the enhancement of differentiation to myotube by taurine treatment (data not
shown).
In Fig.
29.2c
, the silencing
taut
gene using siRNA technique inhibited the dif-
ferentiation to myotube in the C2C12 cells treated with 20 mM taurine compared to
that in the
control
siRNA-transfected cells. Furthermore, the effect of taurine on the
differentiation to myotube was significantly reduced by b-alanine treatment in a
dose-dependent manner (data no shown).
Search WWH ::
Custom Search